Literature DB >> 32420303

Colonic perforation in a nasopharyngeal carcinoma patient treated with fluorouracil: A case report.

Wei-Jia Lu1, Gong Li2, Lei Gao3.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a commonly encountered type of tumor. Fluorouracil (FU) is an effective treatment providing satisfactory oncologic outcomes in nasopharyngeal carcinoma patients. We describe a unique case of colonic perforation in an NPC patient treated with FU. Thus far, only two cases of intestinal perforation associated with FU treatment have been reported. We hope that the analysis of the relationship between the adverse effects of FU and physiological factors will help to reduce the incidence of colonic perforation in patients with nasopharyngeal carcinoma treated with FU. CASE
SUMMARY: A 67-year-old female patient suffered from NPC stage pT3N2M0. She had a history of three surgical procedures: Partial enterectomy, partial sigmoidectomy, and sigmoidostomy. After the administration of 2.75 g FU, a bloody stool appeared and the patient developed abdominal pain. Subsequent examination indicated colitis and intestinal perforation.
CONCLUSION: FU is a commonly used drug in NPC chemotherapy. The most common adverse effect of FU is gastrointestinal reaction, and the colonic perforation found here is thought to be caused by gastrointestinal mucosal injury consequential to the FU treatment. When selecting chemotherapy drugs, their side effects and the physical condition of patients should be considered, particularly in patients with a history of gastrointestinal surgery. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Chemotherapy; Colonic perforation; Fluorouracil; Nasopharyngeal carcinoma; Reaction

Year:  2020        PMID: 32420303      PMCID: PMC7211521          DOI: 10.12998/wjcc.v8.i9.1693

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  9 in total

1.  The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.

Authors:  R Zhou; J Zhu; X Chen; Y Liu; Y Wang; T Zhang
Journal:  Clin Transl Oncol       Date:  2019-06-04       Impact factor: 3.405

2.  5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.

Authors:  F Fata; I G Ron; N Kemeny; E O'Reilly; D Klimstra; D P Kelsen
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

3.  Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.

Authors:  Yvonne Wettergren; Göran Carlsson; Elisabeth Odin; Bengt Gustavsson
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

4.  Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study.

Authors:  F B Geara; B S Glisson; G Sanguineti; S L Tucker; A S Garden; K K Ang; S M Lippman; G L Clayman; H Goepfert; L J Peters; W K Hong
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

5.  Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids. Report of four cases combining 5-fluorouracil infusion and cisplatin with antiemetics dexamethasone.

Authors:  C C Liaw; J S Huang; H M Wang; C H Wang
Journal:  Cancer       Date:  1993-08-15       Impact factor: 6.860

6.  A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.

Authors:  Ajithkumar Puthillath; Terry Mashtare; Gregory Wilding; Nikhil Khushalani; Lynn Steinbrenner; Mary Ellen Ross; Karen Romano; Michelle Wisniewski; Marwan G Fakih
Journal:  Crit Rev Oncol Hematol       Date:  2008-12-10       Impact factor: 6.312

Review 7.  Management of bevacizumab-associated bowel perforation: a case series and review of the literature.

Authors:  B D Badgwell; E R Camp; B Feig; R A Wolff; C Eng; L M Ellis; J N Cormier
Journal:  Ann Oncol       Date:  2007-11-16       Impact factor: 32.976

8.  Diagnosis and treatment of spontaneous colonic perforation: analysis of 10 cases.

Authors:  Bo Yang; Huai-Kun Ni
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

9.  The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.

Authors:  Gregory P Sfakianos; T Michael Numnum; Caitlin B Halverson; Deepa Panjeti; James E Kendrick; J Michael Straughn
Journal:  Gynecol Oncol       Date:  2009-06-23       Impact factor: 5.482

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.